Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
Abstract Background Bordetella pertussis infection is a known trigger of atypical hemolytic uremic syndrome (HUS). For patients suspected of having atypical HUS, prompt plasma exchange/infusion (PE/PI) or eculizumab (ECZ) treatment is recommended. Case presentation We report a 1-month-old female inf...
Main Authors: | Ken Saida, Masao Ogura, Yuji Kano, Shingo Ishimori, Takahisa Yoshikawa, Hiroko Nagata, Mai Sato, Koichi Kamei, Kenji Ishikura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-018-1168-y |
Similar Items
-
Atypical hemolytic uremic syndrome and eculizumab therapy in children
by: Seong Heon Kim, et al.
Published: (2018-02-01) -
Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin
by: Margaret M. Williams, et al.
Published: (2016-02-01) -
Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up
by: Ken Saida, et al.
Published: (2019-12-01) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021-04-01) -
Transmission of Bordetella holmesii during Pertussis Outbreak, Japan
by: Hajime Kamiya, et al.
Published: (2012-07-01)